Skip to main content
Top
Published in: Malaria Journal 1/2015

Open Access 01-12-2015 | Methodology

Characterization and optimization of the haemozoin-like crystal (HLC) assay to determine Hz inhibiting effects of anti-malarial compounds

Authors: Carolina Tempera, Ricardo Franco, Carlos Caro, Vânia André, Peter Eaton, Peter Burke, Thomas Hänscheid

Published in: Malaria Journal | Issue 1/2015

Login to get access

Abstract

Background

The haem-haemozoin biocrystallization pathway is an attractive target where several efficacious and safe anti-malarial drugs act. Consequently, in vitro haemozoin (Hz) inhibition assays have been developed to identify novel compounds. However, results may differ between assays and often require complex methods or sophisticated infrastructure. The recently reported growth of haemozoin-like crystals (HLC) appears to be a simple alternative although the endproduct is structurally different to Hz. This study set out to characterize this assay in depth, optimize it, and assess its performance.

Methods

The HLC assay was used as previously described but a range of different growth conditions were examined. Obtained HLCs were investigated and compared to synthetic (sHz) and natural haemozoin (nHz) using scanning electron microscopy, powder X-ray diffraction (PXRD), Fourier Transform Infrared spectroscopy (FTIR) and Raman spectroscopy (RS). Interactions of HLC with quinolines was analysed using RS. Inhibitory effects of currently used anti-malarial drugs under four final growth conditions were established.

Results

HLC growth requires Mycoplasma Broth Base, Tween 80, pancreatin, and lysed blood or haemin. HLCs are similar to nHz and sHz in terms of solubility, macroscopic and microscopic appearance although PXRD, FTIR and RS confirm that the haem aggregates of HLCs are structurally different. RS reveals that CQ seems to interact with HLCs in similar ways as with Hz. Inhibition of quinoline drugs ranged from 62.5 µM (chloroquine, amodiaquine, piperaquine) to 500 µM in mefloquine.

Conclusions

The HLC assay provides data on inhibiting properties of compounds. Even if the end-product is not structurally identical to Hz, the inhibitory effects appear consistent with those obtained with sHz assays, as illustrated by the results obtained for quinolines. The assay is simple, inexpensive, robust, reproducible and can be performed under basic laboratory conditions with a simple visual positive/negative read-out.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Mok S, Ashley EA, Ferreira PE, Zhu L, Lin Z, Yeo T, et al. Drug resistance. Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance. Science. 2015;347:431–5.CrossRefPubMed Mok S, Ashley EA, Ferreira PE, Zhu L, Lin Z, Yeo T, et al. Drug resistance. Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance. Science. 2015;347:431–5.CrossRefPubMed
3.
go back to reference Krishna S, Kremsner PG. Antidogmatic approaches to artemisinin resistance: reappraisal as treatment failure with artemisinin combination therapy. Trends Parasitol. 2013;29:313–7.CrossRefPubMed Krishna S, Kremsner PG. Antidogmatic approaches to artemisinin resistance: reappraisal as treatment failure with artemisinin combination therapy. Trends Parasitol. 2013;29:313–7.CrossRefPubMed
5.
go back to reference Visser BJ, van Vugt M, Grobusch MP. Malaria: an update on current chemotherapy. Expert Opin Pharmacother. 2014;15:2219–54.CrossRefPubMed Visser BJ, van Vugt M, Grobusch MP. Malaria: an update on current chemotherapy. Expert Opin Pharmacother. 2014;15:2219–54.CrossRefPubMed
6.
go back to reference Held J, Jeyaraj S, Kreidenweiss A. Antimalarial compounds in Phase II clinical development. Expert Opin Investig Drugs. 2015;24:363–82.CrossRefPubMed Held J, Jeyaraj S, Kreidenweiss A. Antimalarial compounds in Phase II clinical development. Expert Opin Investig Drugs. 2015;24:363–82.CrossRefPubMed
7.
go back to reference Rehman K, Lotsch F, Kremsner PG, Ramharter M. Haemolysis associated with the treatment of malaria with artemisinin derivatives: a systematic review of current evidence. Int J Infect Dis. 2014;29:268–73.CrossRefPubMed Rehman K, Lotsch F, Kremsner PG, Ramharter M. Haemolysis associated with the treatment of malaria with artemisinin derivatives: a systematic review of current evidence. Int J Infect Dis. 2014;29:268–73.CrossRefPubMed
8.
go back to reference Hempelmann E. Hemozoin biocrystallization in Plasmodium falciparum and the antimalarial activity of crystallization inhibitors. Parasitol Res. 2007;100:671–6.CrossRefPubMed Hempelmann E. Hemozoin biocrystallization in Plasmodium falciparum and the antimalarial activity of crystallization inhibitors. Parasitol Res. 2007;100:671–6.CrossRefPubMed
9.
go back to reference Kumar S, Guha M, Choubey V, Maity P, Bandyopadhyay U. Antimalarial drugs inhibiting hemozoin (beta-hematin) formation: a mechanistic update. Life Sci. 2007;80:813–28.CrossRefPubMed Kumar S, Guha M, Choubey V, Maity P, Bandyopadhyay U. Antimalarial drugs inhibiting hemozoin (beta-hematin) formation: a mechanistic update. Life Sci. 2007;80:813–28.CrossRefPubMed
10.
go back to reference Weissbuch I, Leiserowitz L. Interplay between malaria, crystalline hemozoin formation, and antimalarial drug action and design. Chem Rev. 2008;108:4899–914.CrossRefPubMed Weissbuch I, Leiserowitz L. Interplay between malaria, crystalline hemozoin formation, and antimalarial drug action and design. Chem Rev. 2008;108:4899–914.CrossRefPubMed
11.
go back to reference Srivastava IK, Vaidya AB. A mechanism for the synergistic antimalarial action of atovaquone and proguanil. Antimicrob Agents Chemother. 1999;43:1334–9.PubMedCentralPubMed Srivastava IK, Vaidya AB. A mechanism for the synergistic antimalarial action of atovaquone and proguanil. Antimicrob Agents Chemother. 1999;43:1334–9.PubMedCentralPubMed
12.
go back to reference Gregson A, Plowe CV. Mechanisms of resistance of malaria parasites to antifolates. Pharmacol Rev. 2005;57:117–45.CrossRefPubMed Gregson A, Plowe CV. Mechanisms of resistance of malaria parasites to antifolates. Pharmacol Rev. 2005;57:117–45.CrossRefPubMed
14.
17.
go back to reference Klonis N, Creek DJ, Tilley L. Iron and heme metabolism in Plasmodium falciparum and the mechanism of action of artemisinins. Curr Opin Microbiol. 2013;16:722–7.CrossRefPubMed Klonis N, Creek DJ, Tilley L. Iron and heme metabolism in Plasmodium falciparum and the mechanism of action of artemisinins. Curr Opin Microbiol. 2013;16:722–7.CrossRefPubMed
18.
go back to reference Haynes RK, Cheu KW, N’Da D, Coghi P, Monti D. Considerations on the mechanism of action of artemisinin antimalarials: part 1–the ‘carbon radical’ and ‘heme’ hypotheses. Infect Disord Drug Targets. 2013;13:217–77.CrossRefPubMed Haynes RK, Cheu KW, N’Da D, Coghi P, Monti D. Considerations on the mechanism of action of artemisinin antimalarials: part 1–the ‘carbon radical’ and ‘heme’ hypotheses. Infect Disord Drug Targets. 2013;13:217–77.CrossRefPubMed
19.
go back to reference Chen MM, Shi L, Sullivan DJ Jr. Haemoproteus and Schistosoma synthesize heme polymers similar to Plasmodium hemozoin and beta-hematin. Mol Biochem Parasitol. 2001;113:1–8.CrossRefPubMed Chen MM, Shi L, Sullivan DJ Jr. Haemoproteus and Schistosoma synthesize heme polymers similar to Plasmodium hemozoin and beta-hematin. Mol Biochem Parasitol. 2001;113:1–8.CrossRefPubMed
20.
go back to reference Oliveira MF, Kycia SW, Gomez A, Kosar AJ, Bohle DS, Hempelmann E, et al. Structural and morphological characterization of hemozoin produced by Schistosoma mansoni and Rhodnius prolixus. FEBS Lett. 2005;579:6010–6.CrossRefPubMed Oliveira MF, Kycia SW, Gomez A, Kosar AJ, Bohle DS, Hempelmann E, et al. Structural and morphological characterization of hemozoin produced by Schistosoma mansoni and Rhodnius prolixus. FEBS Lett. 2005;579:6010–6.CrossRefPubMed
21.
go back to reference Sigala PA, Goldberg DE. The peculiarities and paradoxes of Plasmodium heme metabolism. Annu Rev Microbiol. 2014;68:259–78.CrossRefPubMed Sigala PA, Goldberg DE. The peculiarities and paradoxes of Plasmodium heme metabolism. Annu Rev Microbiol. 2014;68:259–78.CrossRefPubMed
22.
go back to reference Pagola S, Stephens PW, Bohle DS, Kosar AD, Madsen SK. The structure of malaria pigment b-haematin. Nature. 2000;404:4. Pagola S, Stephens PW, Bohle DS, Kosar AD, Madsen SK. The structure of malaria pigment b-haematin. Nature. 2000;404:4.
23.
go back to reference Noland GS, Briones N, Sullivan DJ. The shape and size of hemozoin crystals distinguishes diverse Plasmodium species. Mol Bioch Parasitol. 2003;130:91–9.CrossRef Noland GS, Briones N, Sullivan DJ. The shape and size of hemozoin crystals distinguishes diverse Plasmodium species. Mol Bioch Parasitol. 2003;130:91–9.CrossRef
24.
go back to reference Huy NT, Uyen DT, Maeda A, Trang DT, Oida T, Harada S, et al. Simple colorimetric inhibition assay of heme crystallization for high-throughput screening of antimalarial compounds. Antimicrob Agents Chemother. 2007;51:350–3.PubMedCentralCrossRefPubMed Huy NT, Uyen DT, Maeda A, Trang DT, Oida T, Harada S, et al. Simple colorimetric inhibition assay of heme crystallization for high-throughput screening of antimalarial compounds. Antimicrob Agents Chemother. 2007;51:350–3.PubMedCentralCrossRefPubMed
25.
go back to reference Ncokazi KK, Egan TJ. A colorimetric high-throughput beta-hematin inhibition screening assay for use in the search for antimalarial compounds. Anal Biochem. 2005;338:306–19.CrossRefPubMed Ncokazi KK, Egan TJ. A colorimetric high-throughput beta-hematin inhibition screening assay for use in the search for antimalarial compounds. Anal Biochem. 2005;338:306–19.CrossRefPubMed
26.
go back to reference Basilico N, Pagani E, Monti D, Olliaro P, Taramelli D. A microtitre-based method for measuring the haem polymerization inhibitory activity (HPIA) of antimalarial drugs. J Antimicrob Chemother. 1998;42:55–60.CrossRefPubMed Basilico N, Pagani E, Monti D, Olliaro P, Taramelli D. A microtitre-based method for measuring the haem polymerization inhibitory activity (HPIA) of antimalarial drugs. J Antimicrob Chemother. 1998;42:55–60.CrossRefPubMed
27.
go back to reference Parapini S, Basilico N, Pasini E, Egan TJ, Olliaro P, Taramelli D, et al. Standardization of the physicochemical parameters to assess in vitro the beta-hematin inhibitory activity of antimalarial drugs. Exp Parasitol. 2000;96:249–56.CrossRefPubMed Parapini S, Basilico N, Pasini E, Egan TJ, Olliaro P, Taramelli D, et al. Standardization of the physicochemical parameters to assess in vitro the beta-hematin inhibitory activity of antimalarial drugs. Exp Parasitol. 2000;96:249–56.CrossRefPubMed
28.
go back to reference Haynes RK, Monti D, Taramelli D, Basilico N, Parapini S, Olliaro P. Artemisinin antimalarials do not inhibit hemozoin formation. Antimicrob Agents Chemother. 2003;47:1175.PubMedCentralCrossRefPubMed Haynes RK, Monti D, Taramelli D, Basilico N, Parapini S, Olliaro P. Artemisinin antimalarials do not inhibit hemozoin formation. Antimicrob Agents Chemother. 2003;47:1175.PubMedCentralCrossRefPubMed
29.
go back to reference Sandlin RD, Carter MD, Lee PJ, Auschwitz JM, Leed SE, Johnson JD, et al. Use of the NP-40 detergent-mediated assay in discovery of inhibitors of beta-hematin crystallization. Antimicrob Agents Chemother. 2011;55:3363–9.PubMedCentralCrossRefPubMed Sandlin RD, Carter MD, Lee PJ, Auschwitz JM, Leed SE, Johnson JD, et al. Use of the NP-40 detergent-mediated assay in discovery of inhibitors of beta-hematin crystallization. Antimicrob Agents Chemother. 2011;55:3363–9.PubMedCentralCrossRefPubMed
30.
go back to reference Vennerstrom JL, Nuzum EO, Miller RE, Dorn A, Gerena L, Dande PA, et al. 8-Aminoquinolines active against blood stage Plasmodium falciparum in vitro inhibit hematin polymerization. Antimicrob Agents Chemother. 1999;43:598–602.PubMedCentralPubMed Vennerstrom JL, Nuzum EO, Miller RE, Dorn A, Gerena L, Dande PA, et al. 8-Aminoquinolines active against blood stage Plasmodium falciparum in vitro inhibit hematin polymerization. Antimicrob Agents Chemother. 1999;43:598–602.PubMedCentralPubMed
31.
go back to reference Dorn A, Vippagunta SR, Matile H, Jaquet C, Vennerstrom JL, Ridley RG. An assessment of drug-haematin binding as a mechanism for inhibition of haematin polymerisation by quinoline antimalarials. Biochem Pharmacol. 1998;55:727–36.CrossRefPubMed Dorn A, Vippagunta SR, Matile H, Jaquet C, Vennerstrom JL, Ridley RG. An assessment of drug-haematin binding as a mechanism for inhibition of haematin polymerisation by quinoline antimalarials. Biochem Pharmacol. 1998;55:727–36.CrossRefPubMed
32.
go back to reference Hawley SR, Bray PG, Mungthin M, Atkinson JD, O’Neill PM, Ward SA. Relationship between antimalarial drug activity, accumulation, and inhibition of heme polymerization in Plasmodium falciparum in vitro. Antimicrob Agents Chemother. 1998;42:682–6.PubMedCentralPubMed Hawley SR, Bray PG, Mungthin M, Atkinson JD, O’Neill PM, Ward SA. Relationship between antimalarial drug activity, accumulation, and inhibition of heme polymerization in Plasmodium falciparum in vitro. Antimicrob Agents Chemother. 1998;42:682–6.PubMedCentralPubMed
33.
go back to reference Rush MA, Baniecki ML, Mazitschek R, Cortese JF, Wiegand R, Clardy J, et al. Colorimetric high-throughput screen for detection of heme crystallization inhibitors. Antimicrob Agents Chemother. 2009;53:2564–8.PubMedCentralCrossRefPubMed Rush MA, Baniecki ML, Mazitschek R, Cortese JF, Wiegand R, Clardy J, et al. Colorimetric high-throughput screen for detection of heme crystallization inhibitors. Antimicrob Agents Chemother. 2009;53:2564–8.PubMedCentralCrossRefPubMed
34.
go back to reference Sandlin RD, Fong KY, Wicht KJ, Carrell HM, Egan TJ, Wright DW. Identification of beta-hematin inhibitors in a high-throughput screening effort reveals scaffolds with in vitro antimalarial activity. Int J Parasitol Drugs Drug Resist. 2014;4:316–25.PubMedCentralCrossRefPubMed Sandlin RD, Fong KY, Wicht KJ, Carrell HM, Egan TJ, Wright DW. Identification of beta-hematin inhibitors in a high-throughput screening effort reveals scaffolds with in vitro antimalarial activity. Int J Parasitol Drugs Drug Resist. 2014;4:316–25.PubMedCentralCrossRefPubMed
35.
go back to reference Carrasco MP, Newton AS, Goncalves L, Gois A, Machado M, Gut J, et al. Probing the aurone scaffold against Plasmodium falciparum: design, synthesis and antimalarial activity. Eur J Med Chem. 2014;80:523–34.CrossRefPubMed Carrasco MP, Newton AS, Goncalves L, Gois A, Machado M, Gut J, et al. Probing the aurone scaffold against Plasmodium falciparum: design, synthesis and antimalarial activity. Eur J Med Chem. 2014;80:523–34.CrossRefPubMed
36.
go back to reference Young RM, Adendorff MR, Wright AD, Davies-Coleman MT. Antiplasmodial activity: the first proof of inhibition of heme crystallization by marine isonitriles. Eur J Med Chem. 2015;93:373–80.CrossRefPubMed Young RM, Adendorff MR, Wright AD, Davies-Coleman MT. Antiplasmodial activity: the first proof of inhibition of heme crystallization by marine isonitriles. Eur J Med Chem. 2015;93:373–80.CrossRefPubMed
37.
go back to reference Thomas V, Gois A, Ritts B, Burke P, Hanscheid T, McDonnell G. A novel way to grow hemozoin-like crystals in vitro and its use to screen for hemozoin inhibiting antimalarial compounds. PLoS One. 2012;7:e41006.PubMedCentralCrossRefPubMed Thomas V, Gois A, Ritts B, Burke P, Hanscheid T, McDonnell G. A novel way to grow hemozoin-like crystals in vitro and its use to screen for hemozoin inhibiting antimalarial compounds. PLoS One. 2012;7:e41006.PubMedCentralCrossRefPubMed
38.
go back to reference Burdon DW. A novel replicating agent isolated from the human intestinal tract having characteristics shared with Creutzfeldt-Jakob and related agents. J Med Microbiol. 1989;29:145–57.CrossRefPubMed Burdon DW. A novel replicating agent isolated from the human intestinal tract having characteristics shared with Creutzfeldt-Jakob and related agents. J Med Microbiol. 1989;29:145–57.CrossRefPubMed
39.
go back to reference Klingenstein R, Melnyk P, Leliveld SR, Ryckebusch A, Korth C. Similar structure-activity relationships of quinoline derivatives for antiprion and antimalarial effects. J Med Chem. 2006;49:5300–8.CrossRefPubMed Klingenstein R, Melnyk P, Leliveld SR, Ryckebusch A, Korth C. Similar structure-activity relationships of quinoline derivatives for antiprion and antimalarial effects. J Med Chem. 2006;49:5300–8.CrossRefPubMed
40.
go back to reference Korth C, May BC, Cohen FE, Prusiner SB. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci USA. 2001;98:9836–41.PubMedCentralCrossRefPubMed Korth C, May BC, Cohen FE, Prusiner SB. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci USA. 2001;98:9836–41.PubMedCentralCrossRefPubMed
41.
go back to reference Kocisko DA, Baron GS, Rubenstein R, Chen J, Kuizon S, Caughey B. New inhibitors of scrapie-associated prion protein formation in a library of 2000 drugs and natural products. J Virol. 2003;77:10288–94.PubMedCentralCrossRefPubMed Kocisko DA, Baron GS, Rubenstein R, Chen J, Kuizon S, Caughey B. New inhibitors of scrapie-associated prion protein formation in a library of 2000 drugs and natural products. J Virol. 2003;77:10288–94.PubMedCentralCrossRefPubMed
42.
go back to reference Thompson MJ, Louth JC, Little SM, Jackson MP, Boursereau Y, Chen B, et al. Synthesis and evaluation of 1-amino-6-halo-beta-carbolines as antimalarial and antiprion agents. ChemMedChem. 2012;7:578–86.CrossRefPubMed Thompson MJ, Louth JC, Little SM, Jackson MP, Boursereau Y, Chen B, et al. Synthesis and evaluation of 1-amino-6-halo-beta-carbolines as antimalarial and antiprion agents. ChemMedChem. 2012;7:578–86.CrossRefPubMed
43.
go back to reference Slater AF, Swiggard WJ, Orton BR, Flitter WD, Goldberg DE, Cerami A, et al. An iron-carboxylate bond links the heme units of malaria pigment. Proc Natl Acad Sci USA. 1991;88:325–9.PubMedCentralCrossRefPubMed Slater AF, Swiggard WJ, Orton BR, Flitter WD, Goldberg DE, Cerami A, et al. An iron-carboxylate bond links the heme units of malaria pigment. Proc Natl Acad Sci USA. 1991;88:325–9.PubMedCentralCrossRefPubMed
44.
go back to reference Coban C, Ishii KJ, Sullivan DJ, Kumar N. Purified malaria pigment (hemozoin) enhances dendritic cell maturation and modulates the isotype of antibodies induced by a DNA vaccine. Infect Immun. 2002;70:3939–43.PubMedCentralCrossRefPubMed Coban C, Ishii KJ, Sullivan DJ, Kumar N. Purified malaria pigment (hemozoin) enhances dendritic cell maturation and modulates the isotype of antibodies induced by a DNA vaccine. Infect Immun. 2002;70:3939–43.PubMedCentralCrossRefPubMed
45.
go back to reference Wood BR, Langford SJ, Cooke BM, Lim J, Glenister FK, Duriska M, et al. Resonance Raman spectroscopy reveals new insight into the electronic structure of beta-hematin and malaria pigment. J Am Chem Soc. 2004;126:9233–9.CrossRefPubMed Wood BR, Langford SJ, Cooke BM, Lim J, Glenister FK, Duriska M, et al. Resonance Raman spectroscopy reveals new insight into the electronic structure of beta-hematin and malaria pigment. J Am Chem Soc. 2004;126:9233–9.CrossRefPubMed
46.
go back to reference Bohle DS, Dinnebier RE, Madsen SK, Stephens PW. Characterization of the products of the heme detoxification pathway in malarial late trophozoites by X-ray diffraction. J Biol Chem. 1997;272:713–6.CrossRefPubMed Bohle DS, Dinnebier RE, Madsen SK, Stephens PW. Characterization of the products of the heme detoxification pathway in malarial late trophozoites by X-ray diffraction. J Biol Chem. 1997;272:713–6.CrossRefPubMed
47.
go back to reference Bohle DS, Kosar AD, Stephens PW. Phase homogeneity and crystal morphology of the malaria pigment beta-hematin. Acta Crystallogr D Biol Crystallogr. 2002;58:1752–6.CrossRefPubMed Bohle DS, Kosar AD, Stephens PW. Phase homogeneity and crystal morphology of the malaria pigment beta-hematin. Acta Crystallogr D Biol Crystallogr. 2002;58:1752–6.CrossRefPubMed
48.
go back to reference Orjih AU. On the mechanism of hemozoin production in malaria parasites: activated erythrocyte membranes promote beta-hematin synthesis. Exp Biol Med (Maywood). 2001;226:746–52. Orjih AU. On the mechanism of hemozoin production in malaria parasites: activated erythrocyte membranes promote beta-hematin synthesis. Exp Biol Med (Maywood). 2001;226:746–52.
49.
go back to reference Hempelmann E, Motta C, Hughes R, Ward SA, Bray PG. Plasmodium falciparum: sacrificing membrane to grow crystals? Trends Parasitol. 2003;19:23–6.CrossRefPubMed Hempelmann E, Motta C, Hughes R, Ward SA, Bray PG. Plasmodium falciparum: sacrificing membrane to grow crystals? Trends Parasitol. 2003;19:23–6.CrossRefPubMed
50.
go back to reference Kapishnikov S, Weiner A, Shimoni E, Guttmann P, Schneider G, Dahan-Pasternak N, et al. Oriented nucleation of hemozoin at the digestive vacuole membrane in Plasmodium falciparum. Proc Natl Acad Sci USA. 2012;109:11188–93.PubMedCentralCrossRefPubMed Kapishnikov S, Weiner A, Shimoni E, Guttmann P, Schneider G, Dahan-Pasternak N, et al. Oriented nucleation of hemozoin at the digestive vacuole membrane in Plasmodium falciparum. Proc Natl Acad Sci USA. 2012;109:11188–93.PubMedCentralCrossRefPubMed
54.
go back to reference Carter MD, Phelan VV, Sandlin RD, Bachmann BO, Wright DW. Lipophilic mediated assays for beta-hematin inhibitors. Comb Chem High Throughput Screen. 2010;13:285–92.PubMedCentralCrossRefPubMed Carter MD, Phelan VV, Sandlin RD, Bachmann BO, Wright DW. Lipophilic mediated assays for beta-hematin inhibitors. Comb Chem High Throughput Screen. 2010;13:285–92.PubMedCentralCrossRefPubMed
55.
go back to reference Hoang AN, Sandlin RD, Omar A, Egan TJ, Wright DW. The neutral lipid composition present in the digestive vacuole of Plasmodium falciparum concentrates heme and mediates beta-hematin formation with an unusually low activation energy. Biochemistry. 2010;49:10107–16.PubMedCentralCrossRefPubMed Hoang AN, Sandlin RD, Omar A, Egan TJ, Wright DW. The neutral lipid composition present in the digestive vacuole of Plasmodium falciparum concentrates heme and mediates beta-hematin formation with an unusually low activation energy. Biochemistry. 2010;49:10107–16.PubMedCentralCrossRefPubMed
56.
go back to reference Pisciotta JM, Coppens I, Tripathi AK, Scholl PF, Shuman J, Bajad S, et al. The role of neutral lipid nanospheres in Plasmodium falciparum haem crystallization. Biochem J. 2007;402:197–204.PubMedCentralCrossRefPubMed Pisciotta JM, Coppens I, Tripathi AK, Scholl PF, Shuman J, Bajad S, et al. The role of neutral lipid nanospheres in Plasmodium falciparum haem crystallization. Biochem J. 2007;402:197–204.PubMedCentralCrossRefPubMed
57.
go back to reference Fitch CD, Cai GZ, Chen YF, Shoemaker JD. Involvement of lipids in ferriprotoporphyrin IX polymerization in malaria. Biochim Biophys Acta. 1999;1454:31–7.CrossRefPubMed Fitch CD, Cai GZ, Chen YF, Shoemaker JD. Involvement of lipids in ferriprotoporphyrin IX polymerization in malaria. Biochim Biophys Acta. 1999;1454:31–7.CrossRefPubMed
58.
go back to reference Stiebler R, Hoang AN, Egan TJ, Wright DW, Oliveira MF. Increase on the initial soluble heme levels in acidic conditions is an important mechanism for spontaneous heme crystallization in vitro. PLoS One. 2010;5:e12694.PubMedCentralCrossRefPubMed Stiebler R, Hoang AN, Egan TJ, Wright DW, Oliveira MF. Increase on the initial soluble heme levels in acidic conditions is an important mechanism for spontaneous heme crystallization in vitro. PLoS One. 2010;5:e12694.PubMedCentralCrossRefPubMed
59.
go back to reference Gildenhuys J, le Roex T, Egan TJ, de Villiers KA. The single crystal X-ray structure of beta-hematin DMSO solvate grown in the presence of chloroquine, a beta-hematin growth-rate inhibitor. J Am Chem Soc. 2013;135:1037–47.PubMedCentralCrossRefPubMed Gildenhuys J, le Roex T, Egan TJ, de Villiers KA. The single crystal X-ray structure of beta-hematin DMSO solvate grown in the presence of chloroquine, a beta-hematin growth-rate inhibitor. J Am Chem Soc. 2013;135:1037–47.PubMedCentralCrossRefPubMed
60.
go back to reference Jani D, Nagarkatti R, Beatty W, Angel R, Slebodnick C, Andersen J, et al. HDP-a novel heme detoxification protein from the malaria parasite. PLoS Pathog. 2008;4:e1000053.PubMedCentralCrossRefPubMed Jani D, Nagarkatti R, Beatty W, Angel R, Slebodnick C, Andersen J, et al. HDP-a novel heme detoxification protein from the malaria parasite. PLoS Pathog. 2008;4:e1000053.PubMedCentralCrossRefPubMed
61.
go back to reference Plou F, Ferrer M, Nuero O, Calvo M, Alcalde M, Reyes F, et al. Analysis of Tween 80 as an esterase/lipase substrate for lipolytic activity assay. Biotechnol Tech. 1998;12:183–6.CrossRef Plou F, Ferrer M, Nuero O, Calvo M, Alcalde M, Reyes F, et al. Analysis of Tween 80 as an esterase/lipase substrate for lipolytic activity assay. Biotechnol Tech. 1998;12:183–6.CrossRef
62.
go back to reference Henry JB. Clinical diagnosis and management by laboratory methods. 19th ed. Philadelphia: Saunders; 1996. Henry JB. Clinical diagnosis and management by laboratory methods. 19th ed. Philadelphia: Saunders; 1996.
63.
go back to reference Webster GT, Tilley L, Deed S, McNaughton D, Wood BR. Resonance Raman spectroscopy can detect structural changes in haemozoin (malaria pigment) following incubation with chloroquine in infected erythrocytes. FEBS Lett. 2008;582:1087–92.CrossRefPubMed Webster GT, Tilley L, Deed S, McNaughton D, Wood BR. Resonance Raman spectroscopy can detect structural changes in haemozoin (malaria pigment) following incubation with chloroquine in infected erythrocytes. FEBS Lett. 2008;582:1087–92.CrossRefPubMed
64.
go back to reference Sullivan DJ Jr, Gluzman IY, Russell DG, Goldberg DE. On the molecular mechanism of chloroquine’s antimalarial action. Proc Natl Acad Sci USA. 1996;93:11865–70.PubMedCentralCrossRefPubMed Sullivan DJ Jr, Gluzman IY, Russell DG, Goldberg DE. On the molecular mechanism of chloroquine’s antimalarial action. Proc Natl Acad Sci USA. 1996;93:11865–70.PubMedCentralCrossRefPubMed
65.
go back to reference Buller R, Peterson ML, Almarsson Ö, Leiserowitz L. Quinoline binding site on malaria pigment crystal: a rational pathway for antimalaria drug design. Cryst Growth Des. 2002;2:553–62.CrossRef Buller R, Peterson ML, Almarsson Ö, Leiserowitz L. Quinoline binding site on malaria pigment crystal: a rational pathway for antimalaria drug design. Cryst Growth Des. 2002;2:553–62.CrossRef
66.
go back to reference Egan TJ. Interactions of quinoline antimalarials with hematin in solution. J Inorg Biochem. 2006;100:916–26.CrossRefPubMed Egan TJ. Interactions of quinoline antimalarials with hematin in solution. J Inorg Biochem. 2006;100:916–26.CrossRefPubMed
67.
go back to reference Dahl EL, Shock JL, Shenai BR, Gut J, DeRisi JL, Rosenthal PJ. Tetracyclines specifically target the apicoplast of the malaria parasite Plasmodium falciparum. Antimicrob Agents Chemother. 2006;50:3124–31.PubMedCentralCrossRefPubMed Dahl EL, Shock JL, Shenai BR, Gut J, DeRisi JL, Rosenthal PJ. Tetracyclines specifically target the apicoplast of the malaria parasite Plasmodium falciparum. Antimicrob Agents Chemother. 2006;50:3124–31.PubMedCentralCrossRefPubMed
68.
go back to reference Ramya TN, Mishra S, Karmodiya K, Surolia N, Surolia A. Inhibitors of nonhousekeeping functions of the apicoplast defy delayed death in Plasmodium falciparum. Antimicrob Agents Chemother. 2007;51:307–16.PubMedCentralCrossRefPubMed Ramya TN, Mishra S, Karmodiya K, Surolia N, Surolia A. Inhibitors of nonhousekeeping functions of the apicoplast defy delayed death in Plasmodium falciparum. Antimicrob Agents Chemother. 2007;51:307–16.PubMedCentralCrossRefPubMed
Metadata
Title
Characterization and optimization of the haemozoin-like crystal (HLC) assay to determine Hz inhibiting effects of anti-malarial compounds
Authors
Carolina Tempera
Ricardo Franco
Carlos Caro
Vânia André
Peter Eaton
Peter Burke
Thomas Hänscheid
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2015
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/s12936-015-0913-y

Other articles of this Issue 1/2015

Malaria Journal 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.